The round also saw participation from First Star Ventures, Pacific Health Ventures, Grey Sky Venture Partners, and other undisclosed investors.
“Our ultimate goal is to help patients get better sooner by objectively measuring response to therapy.”
Winterlight is developing a proprietary artificial intelligence (AI) technology that combines computational linguistics, cognitive neuroscience, and machine learning to help healthcare professionals assess patients’ cognitive health from short snippets of speech on a tablet computer.
The tablet-based technology aims to quickly and accurately detect cognitive and mental disorders, such as dementia and aphasia, as well as monitor the progress of treatments. Winterlight said the financing will be used to extend its technology to additional disorders, such as schizophrenia and multiple sclerosis, as well as additional languages.
“Our ultimate goal is to help patients get better sooner by objectively measuring response to therapy in the real world through speech,” said Winterlight Labs co-founder and CEO Liam Kaufman. “The technology our team is creating will reshape the way healthcare systems track, screen for and assess the effectiveness of treatments for various central nervous system diseases.”
StartUp HERE Toronto is a publishing partner of Betakit and this article was originally published on their site.